Skip to Content

Intropin (dopamine) Disease Interactions

There are 6 disease interactions with Intropin (dopamine):

Major

Dopamine (applies to Intropin) arrhythmias

Major Potential Hazard, High plausibility.

The use of dopamine is contraindicated in patients with uncorrected tachyarrhythmias or ventricular fibrillation. Dopamine exerts an agonistic action on the beta receptors of the heart which may lead to an increase in heart rate, atrial fibrillation, enhanced A-V conduction, ventricular ectopy, and arrhythmias.

References

  1. Gelfman DM, Ornato JP, Gonzalez ER "Dopamine-induced increase in atrioventricular conduction in atrial fibrillation-flutter." Clin Cardiol 10 (1987): 671-3
  2. "Product Information. Intropin (dopamine)." DuPont Pharmaceuticals, Wilmington, DE.
  3. Tisdale JE, Patel RV, Webb Cr, Borzak S, Zarowitz BJ "Proarrhythmic effects of intravenous vasopressors." Ann Pharmacother 29 (1995): 269-81
Major

Dopamine (applies to Intropin) asthmatics

Major Potential Hazard, Moderate plausibility.

Dopamine injection contains sodium metabisulfite, a sulfite that may cause anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people, such as asthmatic patients.

Major

Dopamine (applies to Intropin) dehydration

Major Potential Hazard, High plausibility.

The use of dopamine has been infrequently associated with significant hypotension especially in dehydrated patients secondary to beta-2 mediated vasodilation. Hypovolemia should be corrected before administering dopamine. Blood pressure and ECG should be monitored at regular intervals. Monitoring of cardiac output and pulmonary wedge pressure is recommended.

References

  1. "Product Information. Intropin (dopamine)." DuPont Pharmaceuticals, Wilmington, DE.
Major

Dopamine (applies to Intropin) ischemic heart disease

Major Potential Hazard, High plausibility.

The use of dopamine may worsen ischemic heart disease. The stimulation of cardiac beta receptors may aggravate ischemic heart disease. Therapy with dopamine should be administered cautiously in patients with ischemic heart disease. Monitoring of ECG, blood pressure, urine flow, and cardiac output is recommended.

References

  1. "Product Information. Intropin (dopamine)." DuPont Pharmaceuticals, Wilmington, DE.
  2. Ebels T, van der Heide JN "Dopamine-induced ischaemia ." Lancet 2 (1977): 762
Major

Dopamine (applies to Intropin) peripheral vascular disease

Major Potential Hazard, High plausibility. Applicable conditions: Peripheral Arterial Disease

The vasoconstrictive actions of dopamine may aggravate occlusive vascular disease (atherosclerosis, arterial embolism, Raynaud's disease, cold injury, diabetic endarteritis, or Buerger's disease). Therapy with dopamine should be administered cautiously in patients with occlusive vascular disease. Patients should be monitored for decreased circulation to the extremities (change in color or temperature of the skin).

References

  1. Stetson JB, Reading GP "Avoidance of vascular complications associated with the use of dopamine." Can Anaesth Soc J 24 (1977): 727-33
  2. Ross M "Dopamine-induced localized cutaneous vasoconstriction and piloerection ." Arch Dermatol 127 (1991): 586-7
  3. Ebels T, van der Heide JN "Dopamine-induced ischaemia ." Lancet 2 (1977): 762
  4. Golbranson FL, Lurie L, Vance RM, Vandell RF "Multiple extremity amputations in hypotensive patients treated with dopamine." JAMA 243 (1980): 1145-6
  5. Boltax RS, Dineen JP, Scarpa FJ "Gangrene resulting from infiltrated dopamine solution." N Engl J Med 296 (1977): 823
  6. Greene SI, Smith JW "Letter: Dopamine gangrene." N Engl J Med 294 (1976): 114
  7. Winkler MJ, Trunkey DD "Dopamine gangrene. Association with disseminated intravascular coagulation." Am J Surg 142 (1981): 588-91
  8. Julka NK, Nora JR "Letter: Gangrene aggravation after use of dopamine." JAMA 235 (1976): 2812-3
View all 8 references
Major

Dopamine (applies to Intropin) pheochromocytoma

Major Potential Hazard, High plausibility.

The use of dopamine is contraindicated in patients with pheochromocytoma. The catecholamine effects of dopamine may aggravate this condition.

References

  1. "Product Information. Intropin (dopamine)." DuPont Pharmaceuticals, Wilmington, DE.

Intropin (dopamine) drug interactions

There are 197 drug interactions with Intropin (dopamine)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.